Long-term cardio- and neurovascular effects of radiotherapy and chemotherapy in patients with Hodgkin's lymphoma

Long-term cardio- and neurovascular effects of radiotherapy and chemotherapy in patients with Hodgkin's lymphoma - geen

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31544

Enrollment

120

Registered

2006-10-20

Start date

2007-10-16

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hodgkin's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients who have been treated for Hodgkin's lymphoma in the past and who survived at least 2 years. Age> 18 years.

Exclusion criteria

Exclusion criteria: Psychiatric disease or inability to give informed consent.

Design outcomes

Primary

Measure	Time frame
The main parameters are the difference in IMT, the elasticity,the degree of stenosis between the irradiated group and the non-irradiated HL group and to the control population. The other main parameter is the extent of coronary atherosclerosis on MRI in the two patients groups.	—

Secondary

Measure	Time frame
To investigate if inflammatory markers which are know to be increased in age-related atherosclerosis are also increased in RT-induced atherosclerosis. The amounts of cerebrovascular events; i.e. TIA or CVA and of cardiovascular disease; i.e. angina pectoris, myocardial infarction, cardiomyopathy, cardiac failure, rhythm-, conduction abnormalities and valvular dysfunction will be studied. Also endocrine dysfunction will be assessed.	—

Measure

Time frame

To investigate if inflammatory markers which are know to be increased in age-related atherosclerosis are also increased in RT-induced atherosclerosis. The amounts of cerebrovascular events; i.e. TIA or CVA and of cardiovascular disease; i.e. angina pectoris, myocardial infarction, cardiomyopathy, cardiac failure, rhythm-, conduction abnormalities and valvular dysfunction will be studied. Also endocrine dysfunction will be assessed.

—

Countries

Netherlands

Outcome results